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Abstract
Background: A new supraglottic device, the LMA-Supreme™, has recently become available for clinical use.
Information on anaesthetic and co-adjuvant requirements for insertion of the LMA-Supreme™ is limited. The present
study aimed to evaluate the optimal effect-site concentration of propofol in 50 % (EC50) of adults necessary for
successful insertion of the LMA-Supreme™ and to examine remifentanil’s effect on propofol requirements.
Methods: Fifty-eight elective patients (aged 18–60 years; ASA (American Society Anaesthesiologists) physical status
classification I and II) scheduled for day surgery were randomly assigned to one of two groups: propofol with saline
or propofol with remifentanil. Anaesthesia was induced by target-controlled infusion according to predetermined
effect-site concentrations of propofol and remifentanil (5 ng.mL−1). The EC50 was calculated using Dixon’s up-and-
down method. Ten minutes following drug administration, LMA-Supreme™ insertion was attempted without the
use of muscle relaxant drugs.
Results: In the propofol + saline group, the EC50 of propofol required for LMA-Supreme™ insertion was 6.32 ±
0.67 μg.mL−1 (95 % CI, 5.69–6.94 μg.mL−1). With the addition of remifentanil at an effect-site concentration of
5 ng.mL−1, the EC50 of propofol required for LMA-Supreme™ insertion was 2.50 ± 0.80 μg.mL−1 (95 % CI,
1.82–3.17 μg.mL−1; p < 0.0001).
Conclusions: The propofol requirement for smooth insertion of the LMA-Supreme™ was 60 % less when
remifentanil (5 ng.mL−1) was co-administered.
Clinical trial registration: Identified as NCT01974648 at www.clinicaltrials.gov.
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Background
The Laryngeal Mask Airway Supreme™ (LMA-Supreme™;
Laryngeal Mask Company Limited, Singapore) is a new,
single-use laryngeal mask airway that was recently intro-
duced and combines some of the features of the LMA-
Fastrach™ and the LMA-ProSeal™. The mask utilizes an
airway tube with an elliptical cross section, which is
intended to facilitate placement without requiring the
insertion of fingers into the mouth. The LMA-Supreme™
incorporates a drainage tube to permit drainage from
and access to the stomach and to provide confirmatory
evidence of correct placement [1]. To minimize acciden-
tal rotation, the airway tube of the LMA-Supreme™ is
much stiffer than that of the LMA-Classic™ or the LMA-
ProSeal™. Recently, there has been a growing interest in
this device because of favourable studies obtained in sev-
eral anaesthetic contexts that have proven its effective-
ness and safety [2, 3].
Propofol has been extensively used for insertion of
supraglottic devices, generally providing optimal condi-
tions. However, co-induction agents such as opioids are
commonly used with propofol to facilitate device inser-
tion and to reduce the dose of propofol along with the
adverse effects associated with large propofol doses.
When administered with propofol, the ultrashort-acting
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opioid remifentanil improves clinical conditions for in-
sertion of supraglottic airways and reduces the concen-
tration of propofol required for this purpose [4].
The propofol requirement for insertion of the LMA-
Supreme™ is unknown. Most available data on anaes-
thetic and co-induction agent requirements for insertion
of the LMA-Supreme™ originate from research focused
on other evaluations of the device, such as the adequacy
of ventilation achieved and the incidence of complica-
tions [2, 3, 5, 6].
Previous studies have shown that the anaesthetic re-
quirements for insertion of different airway devices are
dissimilar; these differences may be related to struc-
tural changes associated with these airway devices that
exert different pressures and forces in the oral and
pharyngeal cavities [7, 8]. Consequently, considering
the structural features of the LMA-Supreme™ (a stiffer
airway tube, similar to that of the LMA-Fastrach™;
large surface area of the inflatable cuff ), we postulated
that these characteristics might influence the anaes-
thetic requirements for its insertion.
The aim of this randomized controlled study was to de-
termine the optimal effect-site concentration of propofol
in 50 % (EC50) of adults necessary for successful insertion
of the LMA-Supreme™ and to evaluate whether remifenta-
nil administration reduces the EC50. We hypothesized that
remifentanil would diminish the effect-site concentration
of propofol required for LMA-Supreme™ insertion.
Methods
This study was a prospective, randomized, double-blind
placebo-controlled trial (trial registry: NCT01974648 at
www.clinicaltrials.gov). Study approval was obtained from
the Institutional Review Board of Hospital Gregorio
Marañón (Chairman Dr. F. Díaz Otero, dated May 3,
2011, code: FIBHGM-ECNC002-2011, Madrid, Spain);
oral and written informed consent was obtained from
the study participants. The study was conducted at Hos-
pital Gregorio Marañón (Madrid, Spain) from May 2012
to June 2013.
The trial was carried out in accordance with the prin-
ciples of the Helsinki Declarations. The CONSORT rec-
ommendations for reporting randomized, controlled
trials were followed.
We enrolled ASA physical status I and II patients aged
18–60 years who were scheduled for general anaesthesia
in our ambulatory surgery unit.
Patients with a potentially difficult airway (Mallampati
III or IV, thyromental distance of less than 6 cm, a limited
mouth opening and/or cervical spine disease, sleep apnoea
syndrome), reactive airway disease, signs of upper respira-
tory infection, and those showing hiatus hernia or
oesophageal reflux were excluded from the study.
The first author (MZ) enrolled and informed the partici-
pants, and the second author (EB), who was not involved in
patient care, generated the allocation sequences using a
computer-generated program. The eligible patients were
randomly assigned to either the propofol + saline group or
the propofol + remifentanil group by simple randomization.
The randomized sequence was stored in sealed opaque
envelopes. If the patient fulfilled the inclusion criteria,
the investigator (EB) opened the sealed envelope in the
operating room. After opening the envelope, the corre-
sponding group assignment was communicated to the
attending anaesthesiologist.
Routine non-invasive monitoring (arterial blood pres-
sure and heart rate), pulse oximetry, and a bispectral index
(BIS) monitor (A- 2000™ version 3.4; Aspect Medical Sys-
tems Inc., Norwood, USA) were attached. The patients re-
ceived 1 mg intravenous midazolam 20 min before
induction of anaesthesia. Haemodynamic parameters were
measured every minute.
The patients were pre-oxygenated with 100 % oxygen
for 3 min. Target-controlled infusions (TCIs) of propofol
and remifentanil were administered with commercial TCI
pumps (Alaris® PK; Cardinal-Health, Rolle, Switzerland)
according to the pharmacokinetic models of Schnider and
Minto, respectively [9, 10].
Anaesthesia was induced using propofol (Diprivan
prefilled syringes containing 1 % propofol; Zeneca Phar-
maceuticals, Macclesfield, UK) at the predetermined
concentration. Propofol infusion was coadministered
with either saline or remifentanil at an effect-site con-
centration of 5 ng.mL−1. The first patient in each group
received an effect-site concentration of propofol of
4.0 μg.mL−1.
Ten minutes following drug administration, a skilled an-
aesthetist (a staff member with more than 100 LMA uses)
inserted the LMA-Supreme™. The LMA-Supreme™ was
placed according to the manufacturer’s recommended in-
sertion technique [1]. A size 4 LMA-Supreme™ was used
for women and a size 5 for men; however, a size 3 was
chosen for patients weighing ≤ 50 kg. After insertion, the
cuff was inflated with air to a maximum pressure of
60 cm H2O using an aneroid barometer (Mallinckrodt™
Anesthesia; Tyco/Healthcare, USA). Neuromuscular
blocking agents were not administered.
Two nurses, who were blinded to the propofol con-
centration, evaluated each patient’s response to LMA-
Supreme™ insertion. They classified the response as
either “movement” or “no movement”. Movement was
defined as the presence of coughing, straining, bucking,
or gross purposeful muscular movement within 1 min
of airway insertion. The presence of these responses to
LMA-Supreme insertion was considered as failure of inser-
tion. Minor movement and hiccups were not considered to
represent movement in this trial. The absence of movement
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to LMA-Supreme insertion was considered as success of
insertion.
Patients experiencing movement received a 1 mg.kg−1
bolus of propofol.
Jaw relaxation was graded according to the previ-
ously reported Muzi score: 1 = fully relaxed, 2 = mild
resistance, 3 = resistance but the jaw could be opened,
and 4 = resistance requiring a dose of propofol [11].
Jaw relaxation and difficulty in mouth opening were
judged solely by the investigator (MZ).
The propofol effect-site concentration used for each
patient was determined by the response of the previous
patient using the modified sequential “up-and-down
method” described by Dixon [12]. Each patient’s re-
sponse determined the concentration of propofol used
for the next patient. The first patient received propofol
at a 4.0 μg.mL−1 effect-site concentration, and the step
size of increases/decreases was 0.5. μg.mL−1. If inser-
tion of the LMA-Supreme™ was a success, the target
propofol effect-site concentration for the next patient
was set 0.5 μg.mL−1 lower than before. If insertion of
the LMA-Supreme™ failed, the target propofol effect-site
concentration for the next patient was set 0.5 μg.mL−1
higher than before. A single measurement was obtained
from each patient, and the sequence was continued until a
sample size of seven crossovers was reached in each
group.
After stable ventilation with oxygen in air, oropharyngeal
leak pressure (OLP) was measured as follows: the expira-
tory valve was closed and fresh gas flow to the patient was
maintained at 3 L.min−1; the rising pressure within the sys-
tem was measured with the pressure gauge and allowed to
increase until it stopped rising (the expiratory valve was
limited to 40 cm H2O) [13].
After the OLP was measured, a 3.5-mm fiberscope
(Karl Storz GmbH & Co. KG, Tuttlingen, Germany)
was introduced 1 cm proximal to the end of the airway
tube, and the laryngeal view was recorded. The fiber-
scope score was classified using an established scoring
system as follows: grade I = vocal cords not seen, II =
vocal cords plus anterior epiglottis seen, III = vocal
cords plus posterior epiglottis seen, and IV = only vocal
cords seen [14].
Haemodynamic data were recorded at baseline (be-
fore induction of anaesthesia), immediately before
LMA-Supreme™ insertion, and every minute after
LMA-Supreme™ insertion for the first 6 min.
Hypotension, defined as a decrease in mean arterial
pressure of more than 30 % compared with pre-
induction values, and bradycardia, defined as a de-
crease in heart rate of more than 30 % compared with
pre-induction values or a heart rate < 40 bpm, were
treated with ephedrine 3 mg or atropine 0.01 mg.kg−1,
respectively.
Statistical analysis
Effect-site propofol concentrations were determined by
calculating the midpoint concentration of all independent
pairs of patients who manifested crossover from a move-
ment response to a non-movement response. The EC50 of
propofol was defined as the average of the crossover mid-
points (mean) in each group. The standard deviation (SD)
of the EC50 represented the SD of the crossover midpoints
of each group. Predicted EC50 values in the propofol + sa-
line and propofol + remifentanil groups were compared
using Student’s t-test.
We also analysed our data using logistic regression
curves to determine the probability of “no movement”
relative to propofol concentration and to obtain propofol
concentrations where 50 % (EC50) and 95 % (EC95) of
the device insertion attempts were successful in both
groups [15].
The airway leak pressures in the propofol + saline and
propofol + remifentanil groups were compared using
Student’s t-test.
Haemodynamic and BIS values were compared by re-
peated measures analysis of variance. The Chi-squared
test, with Fisher’s exact probability test when appropri-
ate, was used for comparing jaw relaxation and fibreop-
tic position.
A p-value of less than 0.05 was considered statistically
significant.
All statistical analyses were performed with the SPSS-
20 software package (IBM Corp., NY, USA).
Sample size
Dixon methodology suggests that the experiment has to
be continued until at least four crossovers are reached.
In similar studies in the field of anaesthesia, the number
of crossovers varies between six and eight, with six
crossovers being most common. For this study’s pur-
poses, seven crossovers were considered sufficient to
identify the EC50 of propofol required to insert the
LMA-Supreme™ [12, 16].
Results
A total of seventy patients were assessed for eligibility
(Fig. 1). Of the 65 patients screened, 7 patients were
excluded. Ultimately, 58 patients were randomized and
received their allocated intervention. There were no
significant differences in patient demographics or
scheduled surgeries between the groups (Table 1).
Dose–response data obtained using the up-and-down
method are shown in Figs. 2 and 3.
In the propofol + saline group, the EC50 of propofol
required for LMA-Supreme™ insertion was 6.32 ±
0.67 μg.mL−1 (95 % CI, 5.69–6.94 μg.mL−1). With the
addition of 5 ng.mL−1 of remifentanil, the EC50 of
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propofol required for LMA-Supreme™ insertion was 2.50
± 0.80 μg.mL−1 (95 % CI, 1.82–3.17 μg.mL−1; p < 0.0001).
Using logistic regression curves, the probability of no
movement relative to the propofol concentration was
determined in both groups (Fig. 4). The EC50 and EC95
values were 6.09 (95 % CI, 4.41–8.42 μg.mL−1) and
12.09 (95 % CI, 4.73–30.9 μg.mL−1), respectively, in the
propofol + saline group, versus 2.11 (95 % CI, 1.19–
3.72 μg.mL−1) and 4.33 (95 % CI, 1.37–13.6 μg.mL−1),
respectively, in the propofol + remifentanil group.
Table 2 presents the estimated values from the logistic
and goodness of fit analyses.
In seven patients (three in the propofol + saline group
and four in the propofol + remifentanil group), we ex-
changed the LMA-Supreme™ for a LMA-ProSeal™ be-
cause of inadequate ventilation. All of these patients
exhibited movement after LMA-Supreme™ insertion.
Baseline BIS and haemodynamic data did not differ be-
tween the two groups (Table 3). BIS values, systolic blood
pressure, and diastolic blood pressure decreased through-
out the study period in both groups. Prior to and 1 min
after LMA-Supreme™ insertion, systolic and diastolic
blood pressure decreased significantly more in the propo-
fol + remifentanil group relative to the propofol + saline
Fig. 1 Flow-diagram of patient progress through the phases of the trial. Patients were recruited until a sample size of seven crossovers was
reached in each group






Age (yr) 44 (9) 45 (12)
Female/Male 18/14 14/12
Weight (kg) 78 (13) 77 (14)
Height (cm) 169 (10) 168 (10)










General surgery 5 0
Data are expressed as mean (SD) or number
ASA American society of anesthesiologists physical status, BMI body mass
index, SD standard deviation
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group. However, at 6 min after LMA-Supreme™ insertion,
there were no significant differences in systolic and dia-
stolic pressures between the groups.
Heart rate significantly decreased relative to baseline
values in both groups; notably, heart rate remained
statistically lower in the propofol + remifentanil group
compared with the propofol + saline group throughout
the study period. The number of patients who re-
quired vasopressor or atropine administration for
hypotension or bradycardia (three in each group) did
not statistically differ between the groups.
BIS values decreased from baseline in both groups; how-
ever, after induction, values were statistically lower in the
propofol + saline group compared with the propofol +
remifentanil group (Table 3). None of the patients mani-
fested recall of intraoperative events after anaesthesia.
Patient responsiveness to LMA-Supreme™ insertion did
not significantly differ between the two groups (Table 4).
Fig. 2 Patients’ responses to Laryngeal Mask Airway Supreme™ insertion in the propofol + saline group. Arrows indicate the midpoint of the
effect-site concentration of all independent pairs of patients involving crossover from device insertion failure to successful Laryngeal Mask Airway
Supreme™ insertion
Fig. 3 Patients’ responses to Laryngeal Mask Airway Supreme™ insertion in the propofol + remifentanil group. Arrows indicate the midpoint of the
effect-site concentration of all independent pairs of patients involving crossover from device insertion failure to successful Laryngeal Mask Airway
Supreme™ insertion
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Desaturation to less than 90 % during the anaesthetic in-
duction and LMA-Supreme™ insertion occurred in two pa-
tients, both belonging to the propofol + remifentanil group.
Data regarding airway leak pressure and fibreoptic
position of the airway tube are provided in Table 5.
Discussion
This study determined the EC50 of propofol required for
LMA-Supreme™ insertion with and without remifentanil
at 5 ng.mL−1. We found that the addition of remifentanil
reduced the EC50 of propofol necessary for LMA-
Supreme™ insertion by 60 %. This is in accordance with
previous reports, which have demonstrated that remifen-
tanil reduces the dose of propofol required to blunt pa-
tients’ responses to different noxious stimuli as a
consequence of the pharmacodynamic interactions of
propofol and remifentanil [17].
Several studies have been previously conducted to de-
termine the optimal effect-site concentration of propofol
required for successful supraglottic device insertion, but
most have evaluated the propofol dose required for
Laryngeal Mask Airway Classic™ (LMA-Classic™) inser-
tion. In these studies, the reported EC50 of propofol
needed for LMA-Classic™ insertion ranged from 3.14 to
7.30 μg.mL−1 [18–20]. This variation may be related to
confounding variables associated with the design of
these studies, such as premedication, the use of co-
induction agents, and the employment of different cri-
teria to evaluate the success of insertion.
In our study, in the absence of remifentanil, the effect-
site propofol concentration required to insert the LMA-
Supreme™ in 50 % of patients was 6.32 μg.mL−1, which
falls in the middle of the range described for the LMA-
Classic™. In comparison with other sophisticated supra-
glottic devices, our required doses were higher than
those described for the LMA-ProSeal™ (from 4.32 to
4.94 μg.mL−1) [18]. Given the design of the LMA-
Supreme™, we anticipated that the EC50 of propofol ne-
cessary for insertion would be similar to that described
for the LMA-ProSeal™. However, in a 2013 study of 31
adults, Zaballos and colleagues found that sevoflurane
requirements for LMA-Supreme™ insertion were slightly
Fig. 4 Dose–response curves plotted from logistic analysis of individual propofol concentrations illustrating reactions to LMA-Supreme™ insertion.
EC50 in propofol + saline group: 6.09 μg.mL−1; EC50 in propofol + remifentanil group: 2.11 μg.mL−1; EC95 in propofol + saline group: 12.09 μg.mL−1;
EC95 in propofol + remifentanil group: 4.33 μg.mL−1
Table 2 Estimated values of the logit coefficients
Propofol + saline Propofol + remifentanil
EC50 LMA-Supreme (CI) 6.09 (4.41–8.42 μg.mL−1) 2.11 (1.19–3.72 μg.mL−1)




Goodness of fit chi-squared 2.81 13.24
CI: 95 % confidence interval
p/(1 − p) = B0 + B1X
B0 = intercept; B1 = slope; X = dose of propofol (μg.mL−1)
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higher than the concentrations required for LMA-
ProSeal™ placement (3.03 % versus 2.82 %, respectively)
[21]. This difference might be attributed to the use of
co-induction agents that reduce patients’ responses to
LMA insertion during propofol induction (higher doses
of midazolam and lidocaine were used in the LMA-
ProSeal™ study) [18, 22, 23] or to structural differences
between the two devices resulting in unique mucosal
pressures and different anaesthetic requirements.
Opioids have been extensively used as adjuvants to re-
duce the amount of propofol required to insert different
supraglottic devices. Remifentanil is a potent opioid, with
the relevant advantages of having a faster onset of action, a
predictable offset of action, and not inducing prolonged re-
spiratory depression [4]. Two reports found that remifentanil
boluses of 0.25 and 0.50 μg.kg−1 improved LMA-Classic™
insertion conditions while maintaining haemodynamic
stability when administered concurrently with propofol;
however, remifentanil at 0.5 μg.kg−1 resulted in significant
haemodynamic disturbances [24, 25].
Remifentanil has pharmacokinetic and pharmacody-
namic properties that make it an ideal agent to use with
TCI because it maintains a target opioid concentration
at the effect site with a high degree of accuracy and min-
imal adverse haemodynamic changes [4]. Several reports
have investigated the EC50 of remifentanil when used
with a constant TCI of propofol.
In a study of 20 patients (who were premedicated with
40 mg lidocaine) that employed the up-and-down
method, Kim MK and colleagues found that the EC50 of
remifentanil required for LMA-Classic™ insertion was
3.04 ng.mL−1 in association with a TCI of 3.5 μg.mL−1
propofol. These values are similar to our data, although
we used a higher dose of remifentanil (5 ng.mL−1 instead
of 3.04 ng.mL−1) and, consequently, the EC50 of propofol
was 2.5 μg.mL−1 in our study versus 3.5 μg.mL−1 in
Kim’s report [8].
In a posterior study, Kim SH and colleagues compared
the effect-site concentration of remifentanil required for
Streamlined Liner of the Pharynx Airway (SLIPA™) and
Laryngeal Mask Airway SoftSeal (LMA SoftSeal ™) inser-
tion in adults during a TCI of 3.5 μg.mL−1 propofol. The
authors observed that the EC50 values of remifentanil for
SLIPA™ and LMA SoftSeal insertion were 0.93 and
1.36 ng.mL−1, respectively [26]. This combination of
Table 3 Bispectral index and haemodynamic data in the two study groups
Variable Propofol + saline Propofol + remifentanil
(n = 32) [Mean % difference from baseline] (n = 26) [Mean % difference from baseline]
BIS Baseline 96 (3) 97 (2)
Before SLMA insertion*, ** 36 (12) [63 %] 53 (14) [45 %]
1 min after SLMA insertion*, ** 37 (15) [64 %] 51 (15) [47 %]
6 min after SLMA insertion*, ** 28 (9) [71 %] 42 (16) [57 %]
Systolic BP (mmHg) Baseline 125 (15) 131 (15)
Before SLMA insertion*, ** 108 (13) [14 %] 95 (15) [27 %]
1 min after SLMA insertion*, ** 111 (17) [11 %] 94 (15) [27 %]
6 min after SLMA insertion* 97 (14) [23 %] 92 (11) [29 %]
Diastolic BP (mmHg) Baseline 76 (10) 78 (12)
Before SLMA insertion*, ** 66 (11) [12 %] 54 (12) [29 %]
1 min after SLMA insertion*, ** 68 (11) [12 %] 56 (12) [29 %]
6 min after SLMA insertion* 56 (11) [26 %] 55 (9) [28 %]
Heart rate (bpm) Baseline 72 (18) 71 (10)
Before SLMA insertion*, ** 71 (8) [0.01 %] 58 (9) [18 %]
1 min after SLMA insertion*, ** 74 (12) [0,03 %] 58 (10) [18 %]
6 min after SLMA insertion*, ** 62 (10) [14 %] 54 (8) [24 %]
Data are expressed as mean (SD)
BIS bispectral index, BP blood pressure, SD standard deviation
*p < 0.05; significant difference from baseline (difference within the group)
**p < 0.05; significant difference between the propofol + saline and propofol + remifentanil groups by ANOVA with repeated measurements





n = 32 n = 26
Fully relaxed. 22 13
Mild resistance. 4 4
Resistance but could be opened. 2 3
Resistance requiring a dose of
propofol.
4 6
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remifentanil and propofol yielded lower EC50 values than
the authors had previously reported for the LMA-
Classic™. This discrepancy may be attributed to differences
in the anaesthetic technique used; in the second compara-
tive study mentioned, a combination of 0.05 mg.kg−1 mid-
azolam and 1 mg.kg−1 lidocaine was administrated before
induction, whereas in the former study only 40 mg lido-
caine was co-administered with propofol. Several previous
studies have described the effects of midazolam and lido-
caine in decreasing propofol requirements for LMA-
Classic™ insertion [22, 23]. In our study, we administrated
a fixed midazolam dose of 1 mg without lidocaine; conse-
quently, the EC50 of propofol obtained was higher com-
pared with previous reports. However, we cannot exclude
from consideration the possibility that structural differ-
ences between the LMA-Classic™ and LMA-Supreme™ de-
mand the application of different forces within the
oropharyngeal structures and thereby necessitate different
levels of anaesthesia.
In children, the addition of 7 ng.mL−1 of remifentanil
reduced the EC50 of propofol required for successful
insertion of the LMA-Classic™ (from 5.45 to
2.57 μg.mL−1) and a laryngeal tube (from 5.58 to
2.59 μg.mL−1). We observed a similar reduction in pro-
pofol concentration requirements in our study (from
6.32 to 2.50 μg.mL−1) with a lower remifentanil dose
(5 ng.mL−1) [27]. This dissimilarity may be explained
by pharmacokinetic and pharmacodynamic variations
between paediatric and adult populations.
During the study, patients’ haemodynamic responses
were similar in both groups with the exception of heart
rate, which was strongly affected by remifentanil (Table 2).
This is not an unexpected finding, and it is consistent with
previous reports, which have revealed that the use of
remifentanil is associated with more frequent episodes of
bradycardia compared with other opioids [28].
An interesting finding in our study was that the OLP
was higher (up to 18 % higher) in the propofol + remi-
fentanil group compared with the propofol + saline
group. The depth of anaesthesia, degree of muscle relax-
ation, cuff volume, and intracuff pressure are all factors
that affect the seal between the respiratory tract and
supraglottic devices [29]. However, the intracuff pressure
was identical in all patients, and patients in the propofol
+ saline group had lower BIS values than patients in the
propofol + remifentanil group (Table 2). In principle, the
depth of anaesthesia could influence the seal, although
there are no studies directly addressing this issue. The sig-
nificant difference in the OLP between the two groups
suggests that the combination of propofol and remifenta-
nil results in greater suppression of the pharyngeal reflexes
and possibly the tone of the pharyngeal muscles as well,
thereby enabling a superior seal in the propofol + remifen-
tanil group.
Study limitations
In this study, we could have used a lower step size for pro-
pofol (less than 0.5 μg.mL−1), which would have provided
greater accuracy [18–20]. However, the 0.5 μg.mL−1 step
size is the common increment used in studies evaluating
the EC50 of propofol required to insert supraglottic de-
vices, and this consistent approach allowed us to perform
comparisons. Moreover, if the step size had been reduced,
more subjects would have been required to conduct the
trial.
Although our data showed large inter-individual vari-
ability (Fig. 4), several aspects of our study support the
accuracy of our results. Importantly, the starting propo-
fol dose was close to that reported by other studies. This
allowed us to avoid using a markedly different dose
from the true dose, which would have increased the
number of patients required to achieve the predeter-
mined numbers of crossovers. We also increased the
number of crossovers to seven (instead of the four
crossovers suggested by Dixon’s original design) to im-
prove the accuracy of our data.
In this study, the size of the LMA-Supreme™ was princi-
pally selected based on the sex of the patient (size 4 for fe-
males, size 5 for males) instead of the manufacturer’s
weight-based suggestions. We do not know whether this
approach could have changed the EC50 of propofol ob-
tained in our study. However, sex-based LMA-Supreme™
selection is commonly used in investigations and probably
in the clinical scenario as well [2, 3].
Next, the time needed to obtain equilibration of the pro-
pofol concentrations was 10 min in this study; this long
time is not representative of usual clinical practice. How-
ever, our study aimed to investigate the EC50 of propofol
Table 5 Oropharyngeal leak pressure and fibreoptic position of the airway tube
Propofol + saline Propofol + remifentanil
(n = 32) (n = 26)
Oropharyngeal leak pressure (cm H2O) 22 (3) [21–23] 26 (6) [23–29]*
Fibreoptic position 4/3/2/1 n (%) 11(39)/1(4)/4(14)/12(43) 6(26)/3(13)/8(35)/6(26)
Data are mean (SD) [95 % CI] or percentages
The fibreoptic position was available in 28 patient in propofol + saline group and in 23 patients in propofol + remifentanil group
1 = vocal cords not seen; 2 = vocal cords plus anterior epiglottis seen; 3 = vocal cords plus posterior epiglottis seen; 4 = only vocal cords visible
*p < 0.05 by unpaired Student’s t-test
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required to insert the LMA-Supreme™ according to a pre-
determined methodology, the sequential up-and-down
design. This design, similar to minimal alveolar concentra-
tion (MAC) determination, requires a minimum amount
of time to ensure full propofol equilibration.
Finally, the EC95 is probably more relevant than the
EC50 because this concentration represents anaesthetic
requirements in clinical practice (patients need to be ad-
equately anaesthetized to insert the supraglottic devices).
However, the up-down method is designed to determine
the EC50, and it is possible to estimate the EC95 by ex-
trapolating on the logistic regression curve. In addition,
prior key studies that investigated this topic evaluated
the EC50 of anaesthetics required to insert airway de-
vices. Thus, determination of the EC50 allowed us to
compare our results with those of previous studies.
Finally, the haemodynamic responses observed in our
study are applicable only to healthy patients aged 18–60
years. We cannot assume equivalent haemodynamic toler-
ance in more vulnerable ASA III or IV patients.
Conclusions
Our study demonstrated that the propofol requirement
for smooth insertion of the LMA-Supreme™ was 60 %
less when 5 ng.mL−1 remifentanil was co-administered.
Using the up-and-down method, we determined that the
EC50 of propofol necessary for LMA-Supreme™ insertion
was 2.50 ± 0.80 μg.mL−1 (95 % CI, 1.82–3.17 μg.mL−1)
with remifentanil co-administration at 5 ng.mL−1 and
6.32 μg.mL−1 (95 % CI, 5.69–6.94 μg.mL−1) without con-
current remifentanil.
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